CLAIMS

1. A stable pharmaceutical formulation of α4β7 antibody comprising buffer, sugar and surfactant, wherein the formulation is devoid of free amino acid and salt.

2. In the α4β7 antibody formulation according to claim 1, the concentration of sugar is 60 mg/ml.

3. The α4β7 antibody formulation according to claim 1, the concentration of the antibody is 60 mg/ml.

4. The antibody formulation according to claim 1, the sugar is sucrose, trehalose or sorbitol.

5. The antibody formulation of claim 1, is a liquid or lyophilized formulation.